vs
NOVA LTD.（NVMI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是NOVA LTD.的1.8倍（$772.1M vs $433.3M），NOVA LTD.净利率更高（30.7% vs 12.7%，领先18.0%），Revvity自由现金流更多（$161.8M vs $102.6M）
Nova Ltd.（前身为Nova测量仪器公司）成立于1993年，是一家为半导体制造行业提供先进计量解决方案的上市企业，专注于尺寸、材料及化学计量技术领域，股票同时在纳斯达克全球市场和特拉维夫证券交易所上市，代码为NVMI。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NVMI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$433.3M
净利率更高
NVMI
高出18.0%
12.7%
自由现金流更多
RVTY
多$59.2M
$102.6M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $433.3M | $772.1M |
| 净利润 | $133.1M | $98.4M |
| 毛利率 | 57.6% | — |
| 营业利润率 | 29.7% | 14.5% |
| 净利率 | 30.7% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NVMIRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | $433.3M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | — | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润NVMIRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | $133.1M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率NVMIRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | 57.6% | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率NVMIRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 29.7% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率NVMIRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 30.7% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）NVMIRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $348.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NVMIRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | $348.4M | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益NVMIRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产NVMIRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $102.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 23.7% | 21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.86× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流NVMIRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | $114.2M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流NVMIRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $102.6M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率NVMIRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | 23.7% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度NVMIRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率NVMIRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 0.86× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NVMI
| Products | $351.8M | 81% |
| Services | $81.6M | 19% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
